Antiprogestin cyclophasic hormonal regimen
December 19, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesNovel steroids 11ଲ-arylestradienes, their production, and pharmaceutical preparations containing same 13-alkyl-gonanes, their production, and pharmaceutical preparations containing same Use of antigestagens for softening the nonpregnant cervix Contraceptive implant 11 ଲ-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them 19,11 ଲ-bridged steroids, their manufacture and pharmaceutical preparations containing them Hormone preparation and method Hormone preparation and method Hormone preparation and method Patent #: 5276022 InventorAssigneeApplicationNo. 359159 filed on 12/19/1994US Classes:514/170, Plural Compounds containing cyclopentanohydrophenanthrene ring systems514/171, With additional active ingredient514/179, Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)514/863, Psoriasis514/899MENSTRUAL DISORDERExaminersPrimary: Rollins, John W.International ClassA61K 031/56AbstractThe present invention is directed to cyclophasic hormonal regimens which comprise antiprogestin and progestin for human contraception whereby progestin is administered in the alternating presence and absence of an antiprogestin in effective amounts to upregulate steroid receptor levels or is alternatively dosed with effective amounts of antiprogestin to upregulate steroid receptor levels. The present invention also provides an estrogen containing cyclophasic hormonal regimen for climacteric or menopausal hormone replacement therapy comprising the administration of an effective hormone replacement amount of estrogen in alternating doses with a combined amount of estrogen and an effective amount of antiprogestin to inhibit proliferation of endometrial tissue caused by the administration of the estrogen. | |
